- Home
- PYPD vs CMMB Comparison
PYPD vs CMMB Comparison
Compare PYPD & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- CMMB
- Stock Information
- Founded
- PYPD 2008
- CMMB 2004
- Country
- PYPD Israel
- CMMB Israel
- Employees
- PYPD N/A
- CMMB N/A
- Industry
- PYPD Medical/Dental Instruments
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- CMMB Health Care
- Exchange
- PYPD Nasdaq
- CMMB Nasdaq
- Market Cap
- PYPD 16.5M
- CMMB N/A
- IPO Year
- PYPD 2020
- CMMB N/A
- Fundamental
- Price
- PYPD $3.22
- CMMB $1.68
- Analyst Decision
- PYPD Strong Buy
- CMMB Strong Buy
- Analyst Count
- PYPD 2
- CMMB 3
- Target Price
- PYPD $12.00
- CMMB $7.33
- AVG Volume (30 Days)
- PYPD 29.0K
- CMMB 87.3K
- Earning Date
- PYPD 02-12-2025
- CMMB 11-14-2024
- Dividend Yield
- PYPD N/A
- CMMB N/A
- EPS Growth
- PYPD N/A
- CMMB N/A
- EPS
- PYPD N/A
- CMMB N/A
- Revenue
- PYPD N/A
- CMMB N/A
- Revenue This Year
- PYPD N/A
- CMMB N/A
- Revenue Next Year
- PYPD N/A
- CMMB N/A
- P/E Ratio
- PYPD N/A
- CMMB N/A
- Revenue Growth
- PYPD N/A
- CMMB N/A
- 52 Week Low
- PYPD $2.37
- CMMB $0.45
- 52 Week High
- PYPD $9.20
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- PYPD 53.21
- CMMB 52.44
- Support Level
- PYPD $2.37
- CMMB $1.53
- Resistance Level
- PYPD $3.13
- CMMB $1.71
- Average True Range (ATR)
- PYPD 0.32
- CMMB 0.11
- MACD
- PYPD 0.05
- CMMB -0.01
- Stochastic Oscillator
- PYPD 64.89
- CMMB 39.47
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.